ARVN

NASDAQ · Pharmaceuticals

Arvinas Inc

Small-Cap Stocks Stocks Under $10 Pharmaceutical Stocks Healthcare Stocks

$8.15

+0.01 (+0.12%)

ARVN News2 articles

Pfizer Shares Edge Up as Rigel Completes Veppanu Licensing Deal

Pfizer shares edged up after Rigel completed a Veppanu licensing deal with Arvinas, providing a $35 million payment to Pfizer.

Earnings Jun 16

Pfizer and Arvinas Secure First PROTAC Approval in Breast Cancer

The FDA approved Veppanu, a first-of-its-kind PROTAC pill from Pfizer and Arvinas, for advanced breast cancer with ESR1 mutations. The decision precedes Pfizer's Q1 earnings report.